Advancing your drug or vaccine candidate from late-stage discovery into the clinic is one of the most critical steps in development. This is the phase for making key decisions that will have long-term scientific and business impact, frequently under extreme time and cost pressure. For example, developability and manufacturability issues can arise due to post-translational modifications and aggregation, and immunogenicity risks due to the presence of T-cell epitopes.
To maximize your chances of success, it is essential to de-risk your candidates as early as possible. This presentation will describe how in silico and in vitro protein design and optimization tools can help you to identify and mitigate manufacturing, development and immunogenicity risks, to reduce attrition and to improve the quality and safety of your therapeutic proteins.
Our expert, Yvette Stallwood, PhD, presents our latest information on this topic.
Yvette Stallwood, PhD
Head Cambridge Site and Early Development Services @Lonza
Yvette completed her PhD at the University of Birmingham (UK) & has a background in Virology, Cell & Molecular Biology. She joined Lonza in 2007, initially leading the cell and molecular biology expression group in the Early Development Services department & is now Head Cambridge Site & EDS.